Drug Development
Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.
FEATURED STORIES
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease.
There was a fair amount of clinical trial news last week. Here’s a look.
What has been learned about SARS-CoV-2, the virus that causes COVID-19, in only about 15 months, is truly a historical scientific achievement. And new information continues to come in.
With oncology drugs clocking a disheartening 3.4% success rate, some good news in the field is always appreciated.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AstraZeneca released primary analysis that the vaccine demonstrated 76% efficacy against symptomatic COVID-19, 100% efficacy against severe or critical disease and hospitalizations and 85% efficacy against symptomatic COVID-19 in people 65 years and older.
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.
Study findings published in Alzheimer’s & Dementia: Translational Research and Clinical Interventions suggest Leukine® leads to significant reversal of cognitive impairment and normalizes blood-based biomarkers of dementia in patients with mild-to-moderate Alzheimer’s disease.
The study involved observations in neurologic function, cognition and biomarkers in three repeated administrations of Nurown®, which were given two months apart.
Myovant Sciences and Pfizer announced positive results from the Phase III LIBERTY trial of relugolix combination therapy in women with uterine fibroids.